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Abstract
Cystic fibrosis is a genetic disorder that impairs mucus clearance in the lungs,
causing chronic inflammation and recurrent infections. Several airway clearance
modalities are recommended to improve or preserve lung function, including chest
percussion and exercise. However, there is no clinical consensus on the best treatment
regimen to maximize the effect of airway clearance therapies and exercise. The purpose
of this study is to determine whether a structured order of exercise and airway clearance
therapy improves lung function. Using a randomized study, we will evaluate the
effectiveness of a structured regimen compared to a non-structured regimen by following
lung function over one year. Upon completion, we expect the structured program will
result in improved lung function when compared to the non-structured program. Our
results may benefit cystic fibrosis patients by informing the adoption of structured
exercise and airway clearance practices to improve lung function and quality of life.
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Chapter 1 – Introduction
1.1 Background
Cystic fibrosis (CF) is an autosomal recessive disease that affects 1 in every 3,000
to 4,000 live births.1 It is estimated that over 30,000 people in the United States have CF.
The disease is a result of loss of function mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene,2 which causes decreased chloride and bicarbonate
secretion and impaired fluid transport.3 The most severe clinical impact in terms of
morbidity and mortality of CF is manifested in the lungs.4 CFTR proteins in the lungs are
responsible for maintaining airway pH and fluid balance at the mucosal interface, both of
which ultimately modify the viscosity of mucus.5 Mutations in these proteins cause an
impairment in mucus clearance and makes the lungs more susceptible to mucoid
impaction.6 Impaired mucociliary clearance in CF contributes to bacterial pathogen
colonization and growth that causes recurrent infections and can lead to exacerbations.7
In addition to impaired mucus clearance, the deficiency in bicarbonate secretion
causes decreased pH within the lungs.5 This acidic environment inactivates antimicrobial
peptides in the lungs and results in an impaired host defense. This, in turn, leads to
“chronic non-resolving inflammation driven by continuous recruitment of immune
cells.”5 The immune cells recruited into the lungs release oxidants and proteases that
damage the lung tissue. Ultimately, this excessive inflammatory response leads to the
development of bronchiectasis and further impairments in mucociliary clearance.
Overall, impaired mucus clearance in CF leads to chronic inflammation and tissue
destruction that decreases lung function, increases morbidity, and increases mortality.6
Progressive respiratory insufficiency is the most common cause of mortality for people
with CF.8 In fact, 85% of deaths in cystic fibrosis are due to lung disease.9 Clinically, the
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amount of air expired in the first second of forced expiration, known as FEV1, is used to
monitor disease severity and progression.10 For example, exacerbations have been shown
to directly cause a decrease in lung function and an increase in mortality.11 Importantly,
lower lung function and more frequent exacerbations also negatively impact patients’
health-related quality of life.12,13 The detrimental effects of decreased lung function and
increased exacerbations on patients’ overall health and quality of life underline the
importance of preserving lung function and preventing exacerbations.
With the goal to increase mucus clearance, decrease exacerbations, and improve
lung function,14 patients with CF spend on average 108 minutes performing CF
treatments daily.15 In addition to medical treatments, therapies include airway clearance
therapy (ACT) and exercise. ACT can be accomplished through multiple modalities,
including breathing techniques, percussion, drainage, chest compression, and physical
activity.9 As studies have shown that ACT increases sputum clearance, maintains lung
function, and improves quality of life, it is recommended for all patients with CF.9 Also,
aerobic exercise is recommended as an adjunct to ACT due to its benefit in lung function
as well as overall physical health.
An important part of CF treatment is the use of CFTR modulators. These
medications target specific molecular defects in CFTR proteins and lead to improved or
restored function.16 CFTR modulators improve lung function, decrease the risk of
exacerbations, decrease the rate of lung function decline, and improve mucociliary
clearance.16 Recently available triple combination therapy significantly improved lung
function with an average increase of 10% in FEV1.17 These results marked significant
progress in advancing the treatment options for people with CF.
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In summary, CF is a multiorgan, hereditary disease that adversely impacts the
lungs and leads to a decline in lung function over time. It is critical to moderate this
decline to prevent exacerbations, infections, and respiratory failure. Preservation of lung
function is also important to maintain a higher quality of life for patients. To accomplish
this, patients partake in an extensive treatment regimen with the goal of increasing mucus
clearance, preventing exacerbations, and improving lung function.
1.2 Statement of the Problem
Lung function decline is a common clinical manifestation of cystic fibrosis that
often progresses through adulthood. Since patients spend an extensive amount of time on
treatments to moderate this decline, it would be helpful to ensure that treatments are
performed beneficially. We hypothesize that integrating ACT and exercise would
improve lung function and quality of life for CF patients. Exercise and ACT are both
recommended in the treatment of CF, but there is limited data on a formalized
combination of the two over an intervention period longer than 2-4 days.18-21
This study will combine ACT and exercise with the aim of maximizing the
effectiveness of therapy. Importantly, this study will take place over 1 year, thus allowing
us to longitudinally follow lung function as well as our secondary outcomes. A key
strength of this study is that it will help understand whether the integration of ACT and
exercise plays a significant role in lung function, thus allowing patients to maximize
results with their treatments. The results of this study could inform future
recommendations for how to most effectively perform ACT and exercise in CF.
1.3 Goals and Objectives
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The primary goal of our study is to assess the effectiveness of a structured ACT
and exercise program in improving lung function over 1 year. Our secondary goals are to
evaluate the effect of the structured program on the frequency of exacerbations and selfreported quality of life. Our primary outcome is change in FEV1 over 1 year. This will be
measured quarterly, so changes can be trended during the course of the year. Secondary
outcomes will include number of exacerbations and health-related quality of life.
Exacerbations will be assessed through a medical record chart review and defined
according to previously reported criteria. Quality of life will be measured through a
survey given to patients at each quarterly visit.
1.4 Hypothesis
A structured program of airway clearance therapy and exercise in adults with
cystic fibrosis will significantly improve baseline FEV1 percent predicted over one year
compared to a non-structured program.
1.5 Definitions
Airway Clearance Therapy (ACT): ACT is a broad term that covers a variety of
techniques used to clear mucus from the lungs.22 It includes chest physiotherapy, active
breathing techniques, positive expiratory pressure therapy, vibration, and exercise. This is
usually started at the time of diagnosis and is performed daily.
FEV1: FEV1 is the volume of air forcefully exhaled in 1 second.23 It is measured using
spirometry and used to determine the presence of airflow obstruction. It is often
expressed as a percent predicted value to clinically classify the severity of the disease.
The percent predicted is calculated by comparing to a healthy reference population with
similar height, age, and sex.24
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Chapter 2 – Review of the Literature
2.1 Introduction
A review of the literature was performed from December 6, 2019 through June 5,
2020 using Pubmed, Ovid, Scopus, and Cochrane Medical Library. Full articles were
used after reading the titles and abstracts to ensure topic relevance. The search terms used
for the relationships between our independent and dependent variables included Cystic
Fibrosis, Airway Clearance Therapy, Respiratory Therapy, Physiotherapy, Exercise,
Exercise Therapy, Physical Activity, Lung Function, FEV1, Sputum Production, Sputum
Expectoration, Healthy Adults, Exacerbations, Quality of Life, Adherence, and Treatment
Adherence. Key terms used for information regarding study methodology included Cystic
Fibrosis, Adherence, Age, Lung Function, Lung Function Decline, CFTR Mutation,
Bacterial Colonization, Pseudomonas aeruginosa, Burkholderia cepacia, Triple Therapy,
Spirometry, Spirometry Guidelines, Pulmonary Function Tests, NHANES III, FEV1
Variability, Quality of Life, Cystic Fibrosis Questionnaire Revised, Diagnostic Criteria,
Minimal Clinically Important Difference, Exercise, and Adverse Events.
2.2 Cystic Fibrosis and Airway Clearance Therapy
ACT is used in CF to help facilitate mucus clearance. The physiological
mechanism is likely a combination of multiple effects.1 One is an increase in absolute
peak expiratory flow rate that pushes mucus to the oropharynx. Another is a decrease in
the mucus viscosity as a result of oscillations that leads to increased transport. Lastly,
ACT increases spontaneous coughs that clear mucus through mechanical stimulation.
ACT can be delivered using different modalities. Conventional chest
physiotherapy (CPT) includes postural drainage, percussion, and vibration and has been a
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part of therapy for over forty years.2 More recently, methods like high-frequency chest
wall oscillation (HFCWO) and oscillating positive expiratory pressure (OPEP) have been
introduced with the goal of making ACT easier to adhere to at home. HFCWO works by
creating cough-like forces and vibrations to loosen mucus in the lungs, and OPEP creates
positive pressure to keep airways open while creating vibrations to loosen mucus.
Increasing mucus transport within the lungs is critical to help prevent infections and
inflammation.3 With multiple options for ACT, there have been numerous studies
comparing the efficacy of each modality.
The Cystic Fibrosis Foundation’s (CFF) Pulmonary Therapies Committee
reviewed studies on ACT by focusing on sputum clearance, lung function, exacerbations,
and quality of life.4 Evidence set forth by the CFF review determined that ACT has a
moderate benefit in increased sputum clearance, improved lung function, and better
quality of life. Therefore, the CFF currently recommends ACT for all patients with CF.
The CFF committee also determined that although all of these methods are considered to
be beneficial, there is insufficient data to suggest that one modality of ACT is superior to
another. Therefore, they recommended that the prescribed form of ACT should be
individualized to the patient.
For example, a crossover study evaluated HFCWO and OPEP by randomizing 29
CF patients to 4 weeks of each therapy separated by a 2-week washout period.2 The
primary outcome was spirometry and lung volumes, and the secondary outcomes were
patient satisfaction and compliance. The results showed no significant differences in
FEV1 between the two therapies. Also, since there was no significant decline in lung
function from baseline with either therapy, both options were considered effective. In
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terms of patient opinions, reported efficacy was significantly higher for HFCWO, and
reported convenience was significantly higher for OPEP. Patient preference was 50% for
HCFWO, 37% for OPEP, and 13% still preferred CPT. Lastly, patient reported adherence
rates were similar at 88% for HFCWO and 92% for OPEP.
These results are consistent with the CFF recommendation that no ACT modality
is superior in terms of effectiveness. This study also demonstrates the variation in patient
preferences between HFCWO, OPEP, and CPT. The inclusion of patient preference as an
outcome is a strength of this study because it demonstrates the importance of allowing
patients to choose their ACT method. The results of this study and the current
recommendations both support our reasoning that patients in our study may complete
their preferred method of ACT without significantly confounding our results.
Similar results were found in a non-inferiority study that compared multiple forms
of ACT with FEV1 as the primary outcome.5 They randomized 75 patients with CF to
active breathing, autogenic drainage, positive expiratory pressure (PEP), or oscillating
PEP (OPEP). The frequency and duration of ACT were individualized for the
participants. Lung function measurements were taken at 0, 6, and 12 months. At the end
of 1 year, they found no significant difference (P = 0.35) in FEV1 between all 5
modalities, but they did find a significant decline (P = 0.02) in FEV1 overall. The FEV1
percent predicted change for the whole group was -1.8%.
A strength of this study was allowing subjects to complete their individually
required amount of ACT. The results show that even with varying amounts of ACT, there
was no significant difference between the groups. They used this design because it is
more similar to clinical practice since patients have different requirements and
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preferences for ACT. Since our study timeframe is also 1 year, this approach seems the
most feasible as patient requirements change over time. As a whole, these results support
that if the patients in our study complete their preferred form of ACT for an
individualized amount of time, it should not cause significant differences between
groups.
Another important discussion point from this study is the statistically significant
decline in FEV1 over the year. The decrease of -1.8% of percent predicted FEV1 is
similar to the international average during the study time at -2.0%. Since this study lasted
1 year, the results show the progressive decline in lung function in patients with CF
despite therapies. As our study uses the same time period, we may potentially see a
decline in lung function in both groups, but we expect a slower decline in the intervention
group. This will be reflected in our statistical analysis by using the mean absolute change
in baseline FEV1.
The studies discussed above support the recommended guidelines that ACT is
beneficial, and there are no significant differences between ACT modalities. The results
of these studies also demonstrate the importance of recognizing that CF patients require
different amounts of ACT, and they have different preferences for ACT modalities.
2.3 Exercise
2.3.1 Exercise Benefits in Healthy Adults
It is well understood that exercise has numerous positive health effects and is
frequently encouraged for most adults. For example, a crossover study evaluated the
effect of exercise on lung function.6 They included healthy adults ages 25-55 and
recruited a total of 24,536 participants. Baseline lung function measures were taken, and
participants were categorized to an activity level ranging from sedentary to active. They
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found a significant association between FEV1 and physical activity (measured in miles of
walking or jogging) with a P value of < 0.001. The authors concluded that being
sedentary was associated with lower lung function.
In addition to pulmonary health, exercise also affects quality of life. For example,
a study assigned 36 subjects who did not regularly exercise to 20 minutes of aerobic
exercise 3 times per week in addition to weight training.7 They measured quality of life at
baseline and every 8 weeks for 24 weeks using the Health Status Survey. They found a
significant improvement in physical functioning (P = 0.004), bodily pain (P = 0.005),
general health (P = 0.009), vitality (P < 0.001), and mental health scores (P = 0.005)
compared to controls. A significant improvement was also seen in depression (P = 0.048)
and stress (P = 0.036) in the intervention group compared to controls. The studies
discussed above show the benefit of exercise on both physical and mental health in the
general population. We will apply these concepts to adults with CF and aim to have
similar effects with a structured exercise and ACT program.
2.3.2 Exercise and Cystic Fibrosis
Similar to the results shown in healthy adults, many studies have shown the
benefits of exercise for patients with CF. These benefits include improved aerobic
capacity, quality of life, weight gain, and lung function.8 Multiple proposed mechanisms
contribute to the benefit of exercise on lung function. This includes mechanical vibrations
similar to ACT, increased ventilation, and inhibition of the sodium channel in the
respiratory epithelium that results in increased water content of mucus in the lungs. 9
These mechanisms ultimately result in increased mucus clearance. Conversely, low
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physical activity can cause decreased mucus clearance, thus leading to an increased risk
of infections and ultimately lung function decline.10
The CFF Pulmonary Therapies Committee reviewed the data on the benefit of
aerobic exercise in patients with CF.4 They determined that aerobic exercise should be
recommended to patients as adjunct therapy due to its moderate benefit in airway
clearance, as well as a reduced risk of cardiovascular disease, osteoporosis, and
depression. Despite the benefits of exercise mentioned above and to be discussed below,
disease burden and adherence remain obstacles in implementation.8 Our proposed
intervention will aim to address both of these issues by creating a structured exercise
program to mitigate the severity of lung function decline and improve adherence.
2.3.3 Exercise and Lung Function
Orenstein et al. conducted a 3-month supervised running program for people with
CF while measuring exercise tolerance and pulmonary function.11 It included 35 subjects
who volunteered and were divided into either the exercise or the control group. All
patients completed an initial evaluation including oxygen consumption and pulmonary
function tests by exercising on a bicycle. The control group was instructed to maintain
their usual level of activity, and the exercise group was assigned to three, 1-hour training
sessions per week. The training consisted of a 5-10 minute warm-up with stretching, 10
minutes of jog-walk that increased to 30 minutes over the 3 months, a 5-minute cooldown of slow walking, and lastly recreational games. During the jog-walk, participants
were to measure their heart rate by pulse palpation and maintain 70-85% of their
maximum heart rate. The participants repeated the same initial tests at the end of the 3
months. They found a statistically significant (P < 0.005) improvement in the exercise
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tolerance of the exercise group, and the exercise tolerance of the control group was
slightly lower although not statistically significant. The FEV1 of the control group was
also significantly lower at the end of 3 months compared to baseline. Based on the
results, they concluded that the majority of patients with CF could benefit from a similar
exercise program.
This study helps justify the importance of exercise for patients with CF in
improving exercise tolerance. Although they were unable to show a significant
improvement in lung function, they noted no worsening in any lung function
measurements in the exercise group. The lack of significant data on change in lung
function may in part reflect the short, 3-month time frame of this study. The rate of lung
function decline in FEV1 varies greatly, but a separate study found the median decline in
FEV1 percent predicted to be around 2% per year in middle age.12 Since this is not a
dramatically large difference, and half of the people in the study had less than a 2%
decrease, it is plausible that FEV1 would not vary significantly over 3 months. Our
proposed intervention will last for 1 year, thus providing more data points over time to
measure changes in lung function.
Furthermore, our study’s exercise program will be performed individually instead
of as a group. As a result, our findings will be better generalizable to the CF population
and more easily implemented into each individual’s daily schedule. Lastly, this study did
not follow the number of exacerbations or quality of life as an outcome. As exacerbations
are closely connected to lung function, disease progression, and quality of life, our study
will use these as important secondary outcomes.
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Another study on exercise and lung function in Swiss CF centers randomized 42
participants to strength training, aerobic training, or no exercise.9 The intervention groups
participated in 30-45 minutes of exercise 3 times per week for the first 6 months. For the
first 6 months, participants received phone calls once a month to discuss adherence. For
the following 6 months, participants were encouraged to continue with their assigned
training without phone calls. At 3, 6, 12, and 24 months, participants returned to their
health centers to measure outcomes including FEV1, body composition, and physical
activity. To measure compliance, the strength-training group filled out cards at the gym,
and the aerobic training group wore heart rate monitors. They noted that 80% of all the
participants performed their 3 days of exercise per week, and all participants completed at
least 65% of all training sessions. This data shows that participants were generally
adherent to their assigned exercise program over the 6 months.
The results of this study showed a significant (P < 0.05) improvement in the FEV1
of patients in both of the training groups compared to control at 3, 6, and 12 months.
These differences were noted to range from 8-10% at the 6-month time point. They also
found a significant (P < 0.05) improvement in hyperinflation and aerobic performance in
the training groups compared to the control at 6 months. Unlike the Orenstein et al. study,
this study found a significant change in FEV1 with exercise. The longer study period of a
total of 12 months, with 6 months of intervention, is likely contributory to this result. Our
study will have 1 year of intervention with quarterly measurements to ensure adequate
time to measure changes in lung function. This study used monthly phone calls during the
first 6 months to encourage adherence to the assigned program, and they noted the
improved effects they saw at 6 months began to taper down at the end of 1 year. They
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suggest that for training to be effective, it must be continuously supervised for long-term
results. Our study will use this recommendation in our design to increase adherence to the
assigned interventions. Lastly, similar to the Orenstein et al. study, this study did not
measure exacerbations or quality of life of the participants.
2.3.4 Exercise and Sputum Expectoration
Sputum expectoration is a commonly used outcome in CF. A study by Dwyer et
al. measured sputum production in patients immediately after exercise on a treadmill and
a bicycle compared to resting breathing.13 The study was a 3-day crossover design that
involved fourteen adults with CF in Australia. The participants were assigned to 20
minutes of resting breathing, cycle exercise, or treadmill exercise, during which
ventilation and respiratory flow were measured. Ease of expectoration and sputum
properties were measured before, immediately after, and twenty minutes after resting.
They found no significant differences in the ease of expectoration when comparing
before and after both the treadmill and cycle interventions, but they did see a trend (P =
0.096) in improved ease in the treadmill group compared to control and a significant (P =
0.034) improvement in ease in the cycling group compared to control. They measured
ventilation and respiratory flow in terms of minute ventilation, peak inspiratory flow, and
peak expiratory flow, and all were significantly higher with treadmill exercise and
cycling compared to controls. Overall, this study showed improved ventilation and thus
ease of sputum expectoration with exercise compared to the control group.
This study did not measure our primary outcome of FEV1 and instead focused on
sputum expectoration as its primary outcome. It can be suggested that increased sputum
expectoration leads to decreased infections and exacerbations, thus improving or better
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preserving lung function over time. However, measuring sputum production may not
correlate as well with clinical outcomes as FEV1. In CF, patients range from low-sputum
producers to high-sputum producers, thus resulting in a high degree of variability.14 This
is due to many factors, including the willingness to expectorate, swallowing of sputum,
and differences in cough that alter the mobilization of sputum. Furthermore, individual
production varies depending on day and time. For example, production is usually higher
in the morning. Lastly, it can be difficult to determine if the increase in sputum is due to
increased production or increased clearance. For these reasons, we will measure lung
function over time instead of sputum expectoration.
2.3.5 Exercise and Quality of Life
In addition to lung function and sputum expectoration, exercise has also been
shown to improve the ability to complete activities of daily life (ADLs), and thus leads to
an increased quality of life.10 A study assigned 10 CF patients to a home exercise
program with the primary outcome of the degree of limitation in completing ADLs. The
study started with 8 weeks of a control period during which participants were to maintain
their normal routines, followed by a 12-week cycling program. The daily cycling
program consisted of 3 minutes of warm-up, 15 minutes of training, and 3 minutes of
cool-down and was supervised by a physiotherapist 2 days per week. They measured
exercise tolerance and pulmonary function testing at the start of the 8 weeks, the end of
the 8 weeks, and every 4 weeks during the cycling program. Participants were then
instructed to continue their home program for 4 more weeks, and exercise and pulmonary
testing was measured at completion. They measured ADLs with a survey of 11 activities
that participants filled out at the start and end of the intervention period. The survey
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included activities like eating, dressing, bathing, working, traveling, housework, and
walking.15
They found a significant increase (P = 0.004) in maximal exercise capacity and
maximal oxygen uptake (P = 0.008) between the start and end of the 12-week training
period, but there was no significant change in pulmonary function.10 The lack of a
significant change may again be the result of a short intervention period of 12 weeks.
Although this was adequate time to see changes in exercise capacity, the measures of
lung function likely need a longer period of time to show changes.
This study found a significant improvement in limitations of ADLs over the
training period.10 Since we can suggest an increased ability to complete daily activities
leads to an improved quality of life, this result helps justify our hypothesis that our
structured exercise program will result in an improved quality of life. Also of importance
was that, during the follow-up period, 7 patients continued cycling at home and were able
to maintain or improve their training effects and performance level. This indicates a high
level of adherence even when patients were not supervised closely. The researchers
attributed this result to a combination of the prior supervised period and the ages of the
patients (all > 15 years of age). We hope to have a similar rate of adherence in our study
since our participants will be of older age, and we will design our intervention to
encourage adherence through close follow-up during the intervention period. Overall,
engagement in an exercise program is critical in CF, as evidence shows that poor
adherence can lead to worsening respiratory disease and increased infections.
The studies above show the benefits of exercising to improve exercise tolerance,
lung function, sputum expectoration, and quality of life. The most notable gap in research
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of these studies is the short length of intervention and follow-up periods. Secondly, many
of these studies did not measure the frequency of exacerbations or quality of life as
secondary outcomes. We believe that these are important markers that are directly related
to each other, as are patient satisfaction and adherence. Our goal is to create a structured
exercise and ACT program that improves CF clinical outcomes while being realistic for
the daily lives of patients with CF.
2.4 Airway Clearance Therapy vs. Exercise
ACT and exercise both improve mucociliary clearance to minimize infections and
lung function decline.10 Dwyer et al. compared the effects of exercise versus positive
expiratory pressure (PEP) on anatomical regions of sputum expectoration.16 In this
crossover study, 15 adults were randomized to one intervention per visit that included
constant-load treadmill exercise, PEP, or resting breathing. Participants had an initial visit
for baseline lung function and exercise capacity measurements, and the following 3 visits
were at least 48 hours apart over 2 weeks. The interventions were performed for 20
minutes, and measurements were taken before, immediately after, and within 60 minutes
after. They measured mucus clearance at each time point using a mucus clearance scan of
the right lung, and they counted the number of coughs during the time periods.
They found that treadmill exercise had a significant (P < 0.001) increase in mucus
clearance compared to resting breathing in the intermediate and peripheral regions of the
right lung, but the central region was not significantly different. A trend towards more
spontaneous coughs during treadmill exercise compared to resting breathing was also
noted. PEP therapy led to a significant (P < 0.001) increase in mucus clearance of all
regions of the right lung (central, intermediate, and peripheral) compared to resting

18

breathing, and there was a significant increase in coughs during PEP compared to resting
breathing. In comparing treadmill exercise and PEP, treadmill exercise was associated
with significantly lower mucus clearance in the central region (P < 0.001), but they found
no significant difference between the intermediate or peripheral regions. They concluded
that treadmill exercise was significantly better for mucus clearance than resting breathing,
but PEP was more effective in all lung regions than treadmill exercise.
A limitation of this study is that the PEP therapy included forced expiratory
technique (FET, which is relaxed breathing and huffing), while the treadmill exercise did
not. Researchers noted a significant increase in coughing during PEP compared to
treadmill exercise, and they attribute this to the FET component.16 Since the resting
breathing group was not designed as a control group for number of coughs, they were
unable to determine if the difference in the central region clearance was due to PEP or
FET. They concluded that PEP therapy (including FET) should be included with exercise
to increase clearance of the central region. The results of this study show the potential
benefit of combining exercise and ACT on mucus clearance as opposed to a single
therapy. Our study is using this concept to create a structured program of both therapies,
although our primary outcome is FEV1 and not mucus clearance. Also, the short length of
this study would not have allowed for longitudinal measurements of changes in lung
function as it was only 2 weeks.
2.5 Combined Exercise and Airway Clearance Therapy
Several studies, similar to our proposed intervention, have evaluated the effect of
combining exercise and ACT. A crossover study looked at the acute effect of 60 minutes
of exercise before physiotherapy (PT) by measuring sputum weight.17 Eight patients
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participated in 2, non-consecutive days of exercise plus PT and PT alone. Exercise
consisted of 40 minutes of brisk walking, stretching, cycling, step-ups, jumping, rowing,
and jogging, and PT included postural drainage, percussion, deep breathing, vibrations,
and FET. They measured sputum weight during the 40 minutes of exercise and 20
minutes of rest after (or rest on the PT alone day) and during the 60 minutes of PT plus
30 minutes after completion. Lung function was also measured at baseline, after exercise
or rest, after PT, and 30 minutes after PT.
They found a significant (P = 0.023) difference in total mean sputum weight of
14g with ACT only and 21.5g with ACT plus exercise. The mean sputum weight from
the rest period on the PT alone day was 2.6g compared to 7g during the exercise period
on the exercise plus PT day, although the difference was just outside of significant (P =
0.053). They did find a significant (P = 0.007) difference in mean sputum weight between
the PT period on the PT alone day (11.4g) versus the PT period on the PT plus exercise
day (14.5g). Lastly, they did not find a significant difference in lung function between the
groups. The authors attribute this to the short study period as opposed to long-term
follow-up. These results show an added benefit of combining exercise and PT on sputum
weight, but a longer study would be needed to determine the effect on lung function.
This study is useful in helping us plan our exercise program. They allowed
subjects to determine the maximum workload that was comfortably tolerated in contrast
to measuring a particular goal heart rate or oxygen consumption level. This decision was
made because they felt it was more similar to clinical practice. We agree that measuring
outcomes like oxygen consumption is not feasible for a one-year intervention performed
at home. However, asking subjects to measure their heart rate during exercise would be a
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more practical approach to ensure the exercise intensity is adequate. Another important
outcome of this study is that all patients preferred the day of combined exercise and PT
compared to PT alone. This result is encouraging for the design of our study, as our
subjects will be asked to perform combined sessions.
A similar study compared the amount of sputum expectoration between exercise,
PT, and a combination of both.18 Eighteen subjects were assigned to a random order of 20
minutes of PT, 20 minutes of cycling, 10 minutes of cycling followed by 10 minutes of
PT, and 10 minutes of PT followed by 10 minutes of cycling. They chose the 20-minute
treatment period because they felt it was representative of how long clinically stable
patients needed to clear secretions. The treatments were performed over 4 days, and each
was performed twice daily. They weighed expectorated sputum during the 20-minute
sessions as well as for 30 minutes following and throughout the rest of the day.
Expiratory flow volumes were also measured before treatment, after treatment, and 30
minutes post-treatment.
They found a significantly (P < 0.01) higher amount of sputum production in both
PT alone or PT plus exercise than with exercise alone. This trend was found in both high
and low sputum producers in the study. Lung function measures (FEV1 and FVC) were
not different 30 minutes post-therapy compared to baseline values. However, they did
find a significant (P < 0.05) increase in the immediate measures of FEV1 after 20 minutes
of exercise, although it returned to baseline after 30 minutes. In terms of patient
preference, the study also found that patients preferred exercise followed by PT (P <
0.001). This was because patients felt that it was the most effective, and researches
hypothesized that PT after exercise was more relaxing.
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The results of this study show the importance of including ACT in a daily
regimen to improve mucus expectoration and begin to show a potential added benefit of
combination with exercise. Our study will continue with this idea over a long-term period
as opposed to 4 days. Perhaps the most helpful result of this study in creating our
structured program is the patient preferences. As we are hoping to improve patient
experience and quality of life, we will use this information in the order of our ACT and
exercise with the hope of ultimately increasing adherence. A weakness of this study lies
in its short intervention period, as well as a lack of a washout period between
interventions. In their discussion, the authors concluded that patients could be
recommended to perform a combination of exercise and PT for a daily regimen.
A study by Salh et al. instructed 19 adult patients to use an at-home cycle and
perform 10 minutes 5 days per week.19 The patients were to increase their work rate as
tolerated, and sputum production and lung function were measured at the beginning of
the study and after 2 months. Additionally, they had a smaller sample of 10 patients in the
hospital who were instructed to undergo either 15 minutes of PT or 15 minutes of cycling
followed by a 2-hour period of sputum measurement. They would then perform the other
therapy, either PT or exercise. Sputum was measured during and after the interventions,
and this was continued for 2 days. The regimen was then switched to the opposite order
of PT and exercise for 2 more days. In the larger study, they found a significant increase
in work capacity, oxygen consumption, and minute ventilation after 2 months of exercise.
There was not a significant change in FEV1 or sputum weight, although they noted a
trend in increased sputum production after the intervention period. In the smaller study,
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PT produced significantly (P < 0.01) more sputum than exercise, and there were no
significant differences between the order or PT and exercise.
The larger study showed the benefit of exercise on the outcomes of work capacity
(P = 0.003), oxygen consumption (P < 0.001), and minute ventilation (P = 0.004), thus
showing an increase in exercise tolerance. The study had a short intervention period of 2
months, making it difficult to measure changes in FEV1 longitudinally. The smaller study
showed similar results to studies mentioned in previous sections with a greater sputum
production with PT compared to exercise. In regards to the order of PT and exercise, they
found no difference in their outcomes. A weakness of this study is that they did not
address patient preference with the order of PT and exercise. Based on these results,
researchers stated recommending exercise is reasonable as it may prevent a decline in
lung function due to infected sputum retention. Overall, they believe PT and exercise
should be complementary therapies.
In another study on sputum expectoration by Kriemler et al. in Switzerland, 12
patients were randomized to 3 non-consecutive days of cycling, trampoline, or billiards
(sham group) followed by PT.20 They participated in 30 minutes of the assigned exercise
followed by 30 minutes of PT that consisted of 10 minutes of an oscillator device and 20
minutes of deep maximal inspiration and slow exhalation. After each treatment,
researchers measured sputum expectoration and FEV1. They found a significantly higher
amount of sputum expectoration after the trampoline compared to billiards (P = 0.021)
and a trend of increased sputum expectoration after cycling compared to billiards (P =
0.074). Additionally, they found a similar amount of sputum expectoration after all PT
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sessions regardless of the exercise modality used. However, they did not find a difference
in the FEV1 between any of the groups.
This study is similar to our proposed study in terms of the combined exercise and
PT program but differs in its crossover design and short study period. The short study
period likely contributes to the findings of no significant difference in FEV1. Again, we
expect that a longer treatment period is required to see significant changes in lung
function.
In a crossover study by Reix et al., 34 pediatric CF patients participated both in
one session of 20 minutes of ACT (control) and one session of 20 minutes of combined
exercise and forced expiratory techniques (intervention).21 These sessions were
performed on non-consecutive days. They found a significant improvement in FEV1 after
the intervention session compared to the control session. The relative improvement after
the intervention was 2.7% with a significant mean difference of 3.2% (95% CI 0.5 to 6.0)
compared to the control. Patients also reported a significantly higher satisfaction score
with the intervention group compared to control.
The results of this study show that there may be even an immediate effect on lung
function by combining ACT and exercise as opposed to ACT alone. Although the
researchers note the lower end (0.5%) of the confidence interval is not clinically
important, the upper end (6%) is a clinically important difference. The largest limitation
of this study is the design of only 1 intervention session because it does not provide data
on how long the changes are sustained. Our study utilizes the same concept of combined
ACT and exercise, but it will be performed regularly over 1 year to gather longitudinal
results. The higher satisfaction scores with the inclusion of exercise are also encouraging
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for our study intervention. With improved patient satisfaction comes an improved quality
of life and treatment adherence, both of which are goals with our study.
2.6 FEV1 and Secondary Outcomes (Exacerbations and Quality of Life)
Since FEV1 decline marks disease progression in CF, it is closely related to
exacerbations and quality of life. As the number of exacerbations increases, FEV1 tends
to decrease.22 Using information from the CF Patient Registry, the relationship between
increasing exacerbation rate and decreasing lung function is linear.23 This means that
patients with a higher FEV1, indicating better lung function, have a decreased incidence
of exacerbations. One study followed patients over 3 years and found that those with less
than 1 exacerbation per year had a mean FEV1 change of -4.85%, while those with 1-2
exacerbations had a change of -5.44%, and patients with more than 2 exacerbations had a
change of -6.49%.22 They also found that patients with more than 2 exacerbations per
year had a lower baseline FEV1 as well as a more severe progression in FEV1 decline
compared to those with fewer exacerbations. Additionally, these patients had a
significantly increased risk of death within 3 years. This information demonstrates the
importance of preserving lung function and limiting the number of exacerbations per
year.
Multiple studies have also looked at the impact of cystic fibrosis on quality of life.
Exacerbations are associated with significant decreases in the physical well-being and
psychosocial quality of life of CF subjects.24 Bradley et al. compared quality of life
between people with CF with no pulmonary exacerbation, mild exacerbation, and severe
exacerbation.25 They found that the more severe the exacerbation, the lower the quality of

25

life in multiple aspects like physical function, role limitations, emotional functioning, and
social functioning.
A systematic review of CF and quality of life looked at studies that used the
Cystic Fibrosis Questionnaire – Revised (CFQ-R).26 After evaluating 28 articles, they
concluded that a lower FEV1 has a correlation with physical functioning, respiratory
symptoms, and treatment burden. They also found a significant association between
exacerbations and lower CFQ-R scores. They concluded that since FEV1 and pulmonary
exacerbations have the strongest impact on the health-related quality of life for those with
CF, these are aspects that must be addressed clinically. In our study, we will be looking at
these outcomes to determine the benefit of a structured exercise and ACT program. Our
goal is to ultimately improve lung function and decrease exacerbations to improve quality
of life for people with CF.
2.7 Adherence to Therapy
Adherence can be defined as an “active, voluntary, collaborative involvement of
the patient in a mutually acceptable course of behavior to produce a desired preventative
or therapeutic result.” 27Adherence to therapy is challenging with CF because as lung
function deteriorates over time, the complexity of the therapy increases. Patients are also
living longer, and as a result, they face added social and professional responsibilities in
their daily lives. This has made gathering information on treatment adherence even more
important.
In general, studies have shown that adherence declines with increasing treatment
time and complexity.27 The treatment regimen for CF is time-consuming and includes
oral or inhaled antibiotics, pancreatic enzymes, mucolytic agents, vitamin supplements,
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and physiotherapy treatments. One study found the most common reason reported for
non-adherence was forgetfulness followed by the time and effort commitment.28
Although it can be difficult to measure adherence due to reporting, studies have found
that in CF, antibiotic adherence is around 80-95%, nebulized medication and pancreatic
enzyme adherence is 65-80%, and adherence to vitamins, diet, exercise, and
physiotherapy is 40-55%.27 These numbers show that the components of our intervention,
including exercise and physiotherapy, have the lowest adherence rates. This information
is important for us to account for when designing our structured program. Our goal is to
create a program that can be implemented into the daily lives of people with CF without
significantly increasing their treatment burden. We will encourage adherence during the
intervention period with close follow-up that could be reproducible outside of the study
through CF clinics.
To address adherence, we will implement a similar concept to a study by
Schneiderman-Walker et al.29 This study had 72 participants who were randomized either
to an exercise group or the control group. The exercise group was instructed to partake in
aerobic activity for 20 minutes at least 3 times weekly over 3 years. They had participants
fill out a daily journal that was collected at each 3-month visit. The pages listed the date,
type of activity, duration in minutes, and the intensity of the exercise. They also had
phone calls with the participants every 4-6 weeks. Over 3 years, the study found that the
mean scores in exercise compliance did not vary, and the exercise group had consistently
higher amounts of activity compared to control. These results show that the methods used
were effective, as they did not find a decline in adherence over the 3 years.
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Another way we are designing this study to increase adherence and
generalizability is by allowing participants to make some decisions in their intervention.
One study measured change in lung function over 3 years between those who exercise
regularly and those who do not.30 They allowed the intervention group to choose their
method of exercise, which included the gym, dance, and jogging. Their justification for
the decision was because patient adherence improves when patient preference is
considered in the treatment plans. Despite this, they still found a significant difference
between the two groups in FEV1. In the exercise group, annual FEV1% decline was 0.4%
compared to 1.6% in the control group. Unfortunately, they do not specifically describe
the parameters of the length and frequency of “regular exercise,” but they do mention
that the exercise was mostly all aerobic and at least 3 times weekly.
Using the information from this study, it seems feasible for participants to choose
their method of exercise from a list of acceptable modalities. An additional consideration
is the decision between supervised, partially supervised, and unsupervised participation in
ACT and exercise. Again in line with creating a feasible regimen, supervised exercise
and ACT would greatly increase the costs and personnel time required for a study, as well
as impair generalizability because regularly supervised exercise and ACT is not practical
in the daily lives of those with CF. Another study of 2 years allowed the exercise group to
choose their methods as long as they increased their activity by three 60-minute sessions
per week.31 They continued to have their appointments every 3 months. The study was
able to conclude that a partially supervised and individual-based home exercise program
may be sufficient in changing activity levels for patients. They concluded that the type of
activity likely does not matter in regards to the positive effects. Although less supervision
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may reduce the compliance of participants, we plan to mitigate this through the measures
discussed above including allowing individual preferences, monthly phone calls, and
daily journals.
2.8 Possible Confounders
Lung function is a variable measurement depending on many factors in people
with CF. One possible confounding factor on lung function is age.32 In general, patients
with CF see a decline in FEV1 percent predicted by 2% annually.22 One study followed
lung function in people with CF for 10 years.32 Overall, they found an 8.8% decline in
FEV1%. Another study measured FEV1 over 5 years and found an average total decline
of 11.9%. 33 These studies demonstrate a decline in lung function with increasing age,
which is important to be aware of in our study. As our participants will have a wide age
range, we should expect a wide range of baseline FEV1 measurements.
Also of note, the decline in lung function seems to plateau after reaching a certain
age.12 One study showed the steepest decline to be during childhood and early adulthood
and became a modest decline until the age of 30 when it became more stable. This will
play a role in our study since our study population is adults. For participants over the age
of 30, their natural lung function decline will be less than those under 30. In our study,
this means that those who are older will likely have smaller sizes of effect from our
intervention compared to those who are younger.34 To address this, we will match
subjects by age and baseline FEV1 during analysis.
Along with age, lung function varies based on the type of CF-causing mutation.35
In CF, these mutations are categorized based on the amount of CFTR protein created and
its functional ability at the cell surface.36 The most common CF-causing mutation is
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Phe508del, a class II mutation.37 In subjects harboring this mutation, CFTR protein is
synthesized, but it is misfolded and degraded by proteases before reaching the cell
surface, resulting in minimal to no CFTR function. Those with class I or II CFTR
mutations on both CFTR alleles have significantly lower FEV1 compared to those with at
least one III, IV, or V mutation (milder CF-causing mutations with residual CFTR
function).38 These patients also had a more significant decline in their lung function
during follow-up. Additionally, those with class I or II mutations on both alleles had a
significantly higher rate of Pseudomonas colonization.
Another possible confounder with lung function is the patients’ status of bacterial
colonization. The most common organism in CF is Pseudomonas aeruginosa.39 Once a
person with CF is colonized with P. aeruginosa, it marks a progressive decline in lung
function.40 For example, a study found a significant (P < 0.0001) decline in FEV1 in
patients who were colonized with P. aeruginosa.41 On average, these patients had a 13%
lower FEV1 than those who were not infected. The other opportunistic organism
frequently associated with CF is Burkholderia cepacia.42 A study followed the lung
function of patients with CF who were either colonized with Burkholderia and
Pseudomonas, Pseudomonas alone, or neither for 8 years.40 They found that those who
were not colonized with either had significantly higher FEV1% compared to both of the
other groups. They also found a significant difference in the FEV1 decline between those
with both organisms (-5.4%) versus Pseudomonas alone (-3.9%). This study overall
showed that additional infection with Burkholderia led to an accelerated decline in lung
function compared to those with Pseudomonas alone. We must be aware of this during
our study because if our participants become infected with either organism during the
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study, we can expect to see a greater decline in their lung function. In order to address
this potential confounder, we will match subjects according to sputum microbiology
whenever possible in our analysis.
Lastly and perhaps most importantly, we considered the potential impact of novel
triple-combination CFTR modulator therapies in our study. A treatment combining CFTR
modulators (Elexacaftor, Tezacaftor, and Ivacaftor), known commercially as Trikafta,
became available in 2019.43 Phase 3 trials in patients with the f508del mutation showed a
significant improvement in FEV1 predicted with a mean increase of 10% after 4 weeks.44
There was also a significant improvement in CFQ-R scores with a mean increase of 16
points (4 points is set as the minimal clinically important difference). As 90% of people
with CF are either homozygous or heterozygous for the f508del mutation,45 the majority
of patients have the potential to experience substantial improvements in lung function and
quality of life. As a result, those starting triple therapy will see great increases in their
lung function, thus creating a possible confounder in our study.
The phase 3 trial for Trikafta had a duration of 4 weeks, which was noted to be
shorter than previous phase 3 studies for CFTR modulators that used 24 weeks.44
However, this was chosen because previous studies of other CFTR modulators, including
Tezacaftor-Ivacaftor,46 Lumacaftor-Ivacaftor,47 and Ivacaftor,48 all showed that the
greatest changes in FEV1 occurred within the first 4 weeks of treatment and were then
sustained.44 Therefore, we will assume those who have been on triple combination
therapy for longer than 4 weeks have already seen the largest improvement in their FEV1,
and the medication should no longer be a confounder. Of note, a benefit of the
introduction of triple combination therapy is that a greater amount of patients will have a
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higher lung function that allows them to partake in exercise. This will increase the
number of patients that are medically stable to participate in our study.
2.9 Review of Relevant Methodology
2.9.1 Measuring FEV1
All of the reviewed studies that measured lung function used spirometry.
Spirometry is a form of pulmonary function testing (PFT) that measures volume against
time.49 PFTs are regularly used in medicine to determine the presence of airflow
obstruction to help make a diagnosis. The patient is instructed to take a full inhalation and
then a forceful expiration for as long and as quickly as they are able. Along with several
other measures, this results in the FEV1, the volume of air exhaled in the first second of
forceful expiration. FEV1 is used to monitor disease progression and treatment response
of CF,50 therefore, it is an ideal measurement to follow as a primary outcome.
FEV1 is often expressed as a percent predicted to standardize the results across
different ages, heights, sex, and ethnicities.50 There are several equations used to
calculate the percent predicted. One study used the percentage of the FEV1 of the vital
capacity,11 one used Sherril,9 another used Tammeling,10 and one used Quanjer20 for their
calculations. The Yale Adult CF Program uses the third National Health and Nutrition
Examination Survey (NHANES III) equation. This equation comes from a survey that
collected spirometry data from a sample size of 7,429 people in the United States.51 The
data was used to create reference equations for pulmonary function for Caucasians,
African-Americans, and Mexican-Americans based on age, sex, and height. This study
has multiple strengths, including that it was conducted nationwide and had a diverse
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sample population. As a result, the equations produced are likely to be representative of
the population.
The difficulty in following FEV1 lies in its variability. There are variations seen
when FEV1 is followed over time due to 3 reasons: variability between patients, within a
patient, and due to measurement.50 This shows why some of the short-term studies may
not have provided enough data points to ensure that changes, or a lack of change, were
not due to this variability. Since our study intervention period is 1 year, we will have
more data points to look at overall trends, and thus each individual may serve as his/her
own reference, which will ensure this variability will not have as large of an impact on
our results. To address this issue, one study had each subject perform 3 rounds of
spirometry, and they used the highest results in their data.17 This sounds like a reasonable
way to decrease measurement errors, although if the source of the error is the person
assisting with performing spirometry, then this method may not help. Therefore, most of
the reviewed studies also had the same person assisting the patients with their spirometry
to minimize variability between users.
According to the American Thoracic Society Standardization Guidelines for
Spirometry, the spirometry maneuver should be performed at least 3 times and a
maximum of 8 times.52 The additional maneuvers should be performed if the FEV1 values
are not repeatable between the first 3; this is defined as the difference between the 2
largest FEV1 measurements must be less than or equal to 0.150L. These guidelines are
important to follow so that all spirometry measurements are performed the same, thus
decreasing the amount of variability in our results.
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2.9.2 Survey to Measure Quality of Life
There are many surveys to measure quality of life. One example is the Cystic
Fibrosis Questionnaire-Revised (CFQ-R) designed for patients with CF who are 14 years
or older.53 This survey is ideal for measuring health-related quality of life for several
reasons. The first is that the CFQ-R is specifically designed for people with CF. The
second reason is that the CFQ-R is the most accepted survey to measure quality of life in
patients with CF.26 For example, multiple clinical trials for new CF medications,
including the phase 3 trial of Trikafta,44 used the CFQ-R.53 It is also the survey used at
our primary study location at The Yale Adult CF Program, and patients already fill the
CFQ-R out at each quarterly CF appointment.
2.9.3 Inclusion and Exclusion Criteria
Most studies reviewed and discussed above excluded participants with previous
lung transplant and those who were not deemed clinically stable by their CF provider.
Several of the studies excluded those colonized with B. cepacia. One study excluded
those with non-CF related chronic conditions that would pose a risk with exercising.9
This included esophageal varices, pulmonary bullae, a drop in arterial oxygen saturation
below 80%, or signs of pulmonary hypertension on EKG. These criteria are all
reasonable measures to ensure the safety of the participants in undertaking an exercise
program. Another important parameter for participation is baseline FEV1 values. The
studies reviewed with an FEV1 cutoff used either greater than or equal to 35% predicted
or 40% predicted. Since these values mark severely declined lung function, it is more
likely that the subject would not be able to safely tolerate an increase in physical activity.
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Other inclusion criteria for all studies included a diagnosis of CF, however, the
definition of diagnosis varied between studies. Studies that listed specific criteria for
diagnosis included abnormal sweat test, typical pulmonary or digestive symptoms, family
history of CF, and genetic testing. These criteria are similar to the diagnosis criteria
outlined on DynaMed for CF, which is made by at least 1 of the 3 following criteria: 1)
Elevated sweat chloride concentration, 2) 2 disease defining mutations in CFTR gene, or
3) Organ dysfunction such as lung or gastrointestinal. As our study participants are
subjects with a confirmed diagnosis of CF recruited from the Yale Adult CF Program
Clinic, we will adopt their definition of a CF diagnosis, which is also similar. This
includes a clinical presentation consistent with CF and CFTR sequencing that shows CF
causing mutations in both CFTR alleles.
2.9.4 Recruitment
All but one of the studies reviewed recruited study participants from either one or
multiple CF centers based on their own willingness. One study also used advertisements
in a CF newsletter.16 CF patients attend their clinic every 3 months, so these frequent
visits pose a feasible method for recruitment within the centers. Although not mentioned
in any reviewed studies, another option to increase the number of participants would be
to work with the Cystic Fibrosis Therapeutics Development Network (CF TDN). The
TDN was established by the Cystic Fibrosis Foundation to create access to a larger
patient population for therapeutic trials.54 The CF TDN consists of 91 accredited CF care
centers around the US.55 If more subjects were needed for our research, we could contact
the TDN Coordinating Center to present our study and request that they notify sites that
may be interested in joining. The design of our study would be easily implemented in any
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CF clinic because it utilizes the routinely used FEV1 and health-related quality of life
measurements already applied during routine clinic visits. Therefore, other locations that
may participate in the study would not need additional equipment or measurements.
2.9.5 Sample Size
Although FEV1 is a frequently used outcome measure in CF trials, it is difficult to
determine a minimal clinically important difference (MCID) for the population.56 Instead,
it is argued that the MCID should be based on each individual as lung function varies
greatly with CF. Since this is difficult to standardize, a statistically significant difference
between the intervention and control groups is usually considered a successful trial as
opposed to reaching a specific MCID. This concept is reasonable, but it does pose
additional difficulty in calculating a sample size based on an effect size. Therefore, we
must use the results of previous studies to calculate our sample size as opposed to an
MCID. Of the reviewed studies that combined ACT and exercise, the sample sizes ranged
from 817 to 34.21 Although these sample sizes are all small, the studies found statistical
significance in some or all of their outcomes.
2.9.6 Intervention
In the reviewed studies with an intervention of both exercise and ACT, the
specifications of the regimen varied. The interventions consisted of either: 40 minutes of
exercise prior to 25-40 minutes of ACT,17 30 minutes of exercise followed by 30 minutes
of ACT,20 10 minutes of exercise and 10 minutes of ACT compared to the reverse order
of 10 minutes of ACT and 10 minutes of exercise,18 or 3 periods of 5 minutes of aerobic
exercise spaced by 1.5 minutes of ACT.21 Although all of these studies had a primary
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outcome of sputum expectoration instead of lung function, they all produced significant
results.
In the studies that focused only on the longitudinal effects of exercise and not
ACT, the regimen again varied. The interventions consisted of: 1 hour of training
(stretching, walking/jogging, and recreational activities) 3 times weekly,11 30-45 minutes
of activity 3 times weekly,9 and 21 minutes of cycling daily.10 Two of the studies showed
significant improvements in exercise tolerance with the intervention, 10,11 and one study
showed a significant improvement in FEV1 with the intervention. 9 Based on these
results, all of these exercise interventions could have a significant impact on the lung
function of patients with CF.
Several of these studies implemented measures to ensure a specific intensity of
exercise. One study had patients palpate their pulse and encouraged a heart rate of 7085% of their maximal heart rate,11 another used 70% of maximum heart rate,10 and one
targeted a heart rate of 140-160 beats per minute.20 Five of the studies used VO2 levels of
65%,9 60%,13,16,18 and 50%19 of the patients' peak oxygen capacity to measure exercise
capacity. Of note, 2 of the 3 studies that lasted at least 3 months used heart rate as
opposed to VO2 levels to quantify the exercise,10,11 and the study that used VO2 used
watches that measured heart rate to correlate to their target VO2.9 Perhaps this suggests
that for longer-term studies, heart rate is a more feasible target to follow, especially for
patients at home, as opposed to VO2. One study addressed this issue by allowing patients
to subjectively work at a level they could tolerate.17 They chose this method because it
better represented a clinical situation, and they were still able to find a significant
improvement in sputum expectoration with exercise before ACT.
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2.9.7 Adverse Events
Although exercise is generally recommended as a therapy for CF, no physical
activity comes without risks of possible harm to the body. One study, to identify adverse
events from exercise in those with CF, sent out questionnaires to patients regarding this
issue.57 The survey included pneumothorax, loss of consciousness, and acute dyspnea and
cough (asthma attack) after exercise. They were also able to write in their own adverse
events. The patient survey was completed by 256 patients with a mean weekly average of
3.6 hours of exercise. 67% of the patients had experienced no adverse events, 22% had an
asthma attack, 6% had an injury, 4% had a pneumothorax, and 1% had a loss of
consciousness. Of the answers written in by patients, 4% had worsening arthritis with
exercise, 3% had hemoptysis, and 1% had hypoglycemia with exercise. In summary, this
study found low incidences of adverse events related to exercise in those with CF.
Of the studies discussed that mentioned adverse events, most had none to
report.9,11,16,18 These studies specifically mentioned the absence of cardiac and orthopedic
complications, injuries, pneumothorax, asthma attacks, hypoglycemia, heart rate, and
oxygen saturation. One study had 5 participants with adverse events, which were not
statistically significant between the intervention and control group.21 This included
fatigue, breathlessness, and oxygen desaturation below 92%, and these resolved quickly
with rest. Overall, the risk of any of these possible adverse events is low; however, they
remain important to monitor during our study to ensure the safety of the participants.
2.10 Conclusion
Based on the studies discussed in this section, the individual benefits of ACT and
exercise as treatment modalities in CF are clear. However, there is limited data on the

38

long-term effects of a combined regimen. Available studies combining ACT and exercise
are short-term and often focused on sputum production as opposed to lung function.
These studies, however, have demonstrated the benefit of ACT in preventing
exacerbations in order to better preserve lung function and quality of life. As we note
above, sputum production is a frequently measured outcome, but is fraught by variability
and technical difficulties. More importantly, measurements of sputum clearance may not
directly reflect the clinical impact of exercise and ACT on lung function and quality of
life. Therefore, we concentrate on clinically relevant measurements of FEV1 and quality
of life throughout our study.
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Chapter 3 – Study Methods
3.1 Study Design
Our study will be a prospective randomized controlled trial. Patients will be
randomized to either structured ACT and exercise or unstructured ACT and exercise. The
CF providers and respiratory therapists performing spirometry will be blinded to the
intervention. The intervention period will last 1 year, and subjects will not crossover to
the other intervention. Outcome measurements will occur at 0, 3, 6, 9, and 12 months. At
the end of the study, participants are free to alter their exercise regimens as desired.
Figure 1: Proposed Study Design

3.2 Study Population and Sampling
The study population will be adult patients (≥18 years of age) with a confirmed
diagnosis of CF from The Yale Adult CF Program within the Yale CF Care Center.
Providers at the clinic will be approached to discuss the study, and they will be asked to
recruit patients that fit our eligibility criteria. This sampling method will aim to ensure
that the subjects recruited regularly attend their CF appointments. This is important for
several reasons; the first is that those who regularly go to their appointments will have
more contact with their providers, thus making it easier for the provider to deem the
patient is safe to participate. Second, it will target patients who are motivated and actively
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participate in their own care. Since this study is evaluating an at-home program, it is
likely that those who would participate outside the study would also only be those who
are more motivated. Lastly, if patients attended their previous appointments, it is more
likely they will attend future appointments at which study measurements will take place.
Also, those who attend appointments regularly will have closer follow-up to adjust their
other treatments as needed, which is important for their safety.
3.3 Inclusion
Inclusion criteria will be given to the providers at the CF clinic to screen for
eligible patients – Patients must be 18 years of age and older and deemed stable by their
CF provider to exercise and participate in the study. Also, patients must already use a
form of ACT before starting the study. Women will not be excluded if already pregnant
or if they become pregnant during the study. Patients will be recruited regardless of race
to best represent the population of those with CF, although it should be noted the disease
is more prevalent in Caucasians. Patients who already exercise and those who do not may
be included, as they will be randomized to the intervention.
3.4 Exclusion
Patients with an FEV1 < 40% will be excluded from the study. Those who are
post lung transplant will also be excluded. Patients who have comorbidities other than CF
that inhibit their ability to exercise or affect their lung function will be excluded. This
includes diagnoses of pulmonary hypertension, heart failure, and other advanced lung
diseases like COPD, asthma, and idiopathic pulmonary fibrosis. Lastly, those who have
started taking any CFTR modulator medications within the last 4 weeks will be excluded
(those who have been on a stable dose for longer than 4 weeks will be eligible). These
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exclusion criteria are primarily for the safety of the patients participating in the study to
decrease the chance of any adverse events with exercise. The criteria will also increase
the likelihood that changes in lung function are a result of the intervention as opposed to
other causes. Children are not included in this study because they have different patterns
of lung function decline compared to adults, and the CFQ-R is designed for 14 years of
age and older.
3.5 Subject Protection and Confidentiality
Before the initiation of this study, we will first gain approval by the Yale University
Institutional Review Board (IRB). All participants in the study must complete and sign our
informed consent form. The form will cover important information for the patient and will
be reviewed with study recruitment staff. The consent form will describe the procedures of
the study and the potential risks and benefits. A description of patient confidentiality and
privacy will be included to explain the handling of patient information during the study.
Lastly, the patient will be able to ask any questions regarding the study, and they may take
time to consider joining before signing the form. A sample of the consent form can be found
in Appendix A. The study protocol and patient confidentiality will comply with the Health
Insurance Portability and Accountability Act (HIPAA) regulations. Patient information will
be de-identified and kept confidential. Participation in the study is entirely voluntary, and
participants may withdraw from the study at any time without affecting the care they receive
at the CF clinic. A description on how to withdraw from the study is included in the consent
form.
3.6 Recruitment
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Recruitment will take place over 1 year at The Yale Adult CF Program within The
Yale CF Care Center. Since patients attend the CF clinic every 3 months, this will provide a
large number of potential participants. The providers at the CF clinic will be provided with
study details and inclusion/exclusion criteria and asked to recruit eligible patients. Flyers
will also be sent to the patients of the clinic with information regarding the study and
information on how to enroll. A sample flyer can be found in Appendix B. Additionally, if
more participants are needed, we may recruit from the Adult Cystic Fibrosis Clinic at
Hartford Hospital. This would create a larger pool of patients to sample from while
keeping in proximity to our primary site. Lastly, the study may be presented to the Cystic
Fibrosis Therapeutics Development Network to further recruit participants from CF clinics
around the United States.
3.7 Study Variables and Measures
The independent variable of this study is the regimen of exercise and ACT. The
subjects will be separated into 2 groups: Either structured exercise and ACT
(intervention) or non-structured exercise and ACT (control). The main outcome and
dependent variable of this study is FEV1 percent predicted. This will be measured at
baseline as well as at each quarterly visit during the year. FEV1 will be measured with
spirometry using the most up-to-date American Thoracic Society guidelines and
expressed as percent predicted using the NHANES III equation. Respiratory therapists
within the CF clinic will perform spirometry.
Secondary outcomes will include exacerbation frequency and quality of life.
Exacerbations will be assessed using medical records through an Epic chart review upon
completion of the intervention. An exacerbation will be defined using criteria by Fuchs et
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al.: “A patient treated with parenteral antibiotics for any 4 of the following 12 signs or
symptoms: change in sputum; new or increased hemoptysis; increased cough; increased
dyspnea; malaise, fatigue, or lethargy; temperature above 38 °C; anorexia or weight loss;
sinus pain or tenderness; change in sinus discharge; change in physical examination of
the chest; decrease in pulmonary function by 10 percent or more from a previously
recorded value; or radiographic changes indicative of pulmonary infection.”1 Quality of
life will be measured using the Cystic Fibrosis Questionnaire-Revised (CFQ-R). A copy
of the survey can be found in Appendix C. The survey will be completed at baseline and
each 3-month clinic visit during the year.
Table 1. Primary and Secondary Outcomes
Primary or
Outcome
Secondary
Timeframe
Outcome
Baseline,
Change in
Every 3
FEV1 %
Primary
months for 1
Predicted
year
Change in
Frequency of
Exacerbations
Change in
Quality of Life
Score

Measurement

Importance

Standard
Spirometry,
NHANES III
Equation

Measure
changes in
lung function

Secondary

During
intervention
period (1 year)

Chart Review

Show
frequency of
exacerbations

Secondary

Baseline,
Every 3
months for 1
year

Cystic Fibrosis
Questionnaire Revised

Quantify the
health-related
quality of life
of patients

3.8 Methodology Considerations
3.8.1 Experimental Protocol
The study will consist of a 1-year intervention period. Before starting the
intervention, study-recruiting personnel will discuss exercise parameters with the
subjects. They will be instructed to choose their preferred type of exercise from the
provided list (Appendix D). To ensure subjects are exercising at a high intensity, they
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will be instructed to record their heart rate in their journal before starting exercise, at 15
minutes of exercise, and upon completing 30 minutes of exercise. Study personnel will
demonstrate how to calculate heart rate by counting the heart rate for 15 seconds and
multiplying that number by 4. Subjects will be provided their target heart rate and asked
to increase their intensity if their heart rate is below target when checked at the 15-minute
point. Instructions will also be written in the journal, which can be found in Appendix E.
Calculations for target heart rate can be found in Appendix F.
Subjects randomized to structured ACT and exercise will perform 30 minutes of
exercise immediately followed by ACT 3 times weekly. The length and modality of ACT
will be performed according to the CF provider’s recommendations. If the subject
performs more than 1 session of ACT in a day, they may choose which session to
combine with exercise. Upon completing each session, the participant will fill out their
journal entry for the day. The journal should be filled out every day whether they
exercised or not. For those assigned to the non-structured program, they will also be
instructed to exercise 3 times weekly, but it should be separated by at least 2 hours from
an ACT session. ACT should be performed according to the provider’s
recommendations.
Figure 2. Sample Weekly Schedule of ACT and Exercise

3.8.2 Blinding of Intervention
Blinding of the intervention to the study subjects is not feasible given their active
participation in the intervention. The assignment of the intervention will be blinded to the
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respiratory therapist performing spirometry measurements. Providers will also be blinded
to the intervention. Subjects will be asked to keep their intervention confidential from
their providers.
3.8.3 Blinding of Outcome
The subjects will not be blinded to the outcomes of FEV1% or exacerbation
frequencies. As the study is longitudinal, they should be aware of their lung function
during the year, and they will already be aware of their exacerbations. Subjects will be
blinded to their CFQ-R scores. Providers will not be blinded to any of the outcome
measures for the safety of the participants. This will allow providers to modify treatment
regimens, if needed, due to unexpected changes in lung function or clinical condition.
3.8.4 Assignment of Intervention
Intervention will be assigned using randomizeR software.
3.8.5 Adherence
Adherence will be monitored throughout the study. At home, patients will use a
daily journal to log modality and time spent on exercise and ACT. These logs are to be
brought to every appointment to be reviewed and discussed. During the months the
patient does not have an appointment, they will receive a monthly phone call from study
personnel to discuss adherence and answer any questions.
3.8.6 Monitoring of Adverse Events
Before beginning the study, patients will be made aware of the very low risk of
possible adverse events such as physical injury, an increase in dyspnea or coughing,
hypoglycemia, loss of consciousness, worsening of arthritis, and pneumothorax. At each
office appointment, in addition to spirometry, vitals (blood pressure, heart rate, and
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oxygen saturation) will be measured and compared to previous vitals. Patients will also
be asked if they have noticed any changes in their health or if they have any concerns at
every visit and during every phone call, and they will be encouraged to document these in
their logs. Patients will be instructed to immediately discontinue exercise if they feel that
they are unable to complete a session. The phone number to their CF provider will be
given to all patients to call if they have any questions or concerns.
3.9 Data Collection
Data collection will take place for 1 year. During this time, participants will
continue to have quarterly appointments. At each of these appointments, all participants
will perform spirometry with a respiratory therapist to measure FEV1. They will also
complete the CFQ-R to evaluate their health-related quality of life. Data collection on
exacerbations will take place at the end of the study based on chart review for the year of
the intervention period.
3.10 Sample Size Calculation
The previous studies that combined exercise and ACT used a short-term outcome
follow-up, and did not find significant differences in FEV1 to inform our sample size
calculations for a 1 year intervention design. Therefore, we used a study with a similar
exercise intervention and a longer follow-up period to calculate our sample size. Our
sample size calculation is based on change in FEV1 percent predicted over 6 months in
adults with CF from a study by Kriemler et al.2 The exercise intervention is similar with
30 minutes of exercise 3 times weekly, and subjects received monthly phone calls in
addition to quarterly appointments. The exercise group had an increase in FEV1 of
5.76±3.7% over 6 months, and the control group had a decrease in FEV1 of -4.42±14.7%.
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Using these numbers, and assuming an alpha of 0.05 and power of 90% with a two-tailed
hypothesis, we calculated a sample size of 50. As this study does not directly include
ACT as part of the intervention, and it compares an exercise group to a control group
without specific exercise instructions, in addition to increasing power to 90%, we will
add 10 more subjects to each arm to account for this difference in study design. Also, to
accommodate for a 10% dropout rate, we aim to recruit a total of 77 participants. The
sample size calculation can be found in Appendix G.
3.11 Analysis
The study population will be characterized using descriptive statistics for
parameters including age, sex, race, baseline FEV1, and baseline CFQ-R score (Table 2).
This will utilize both unpaired Student’s t-tests for continuous variables and Chi-squared
tests for categorical variables. All analyses will be performed using the intention to treat
principle, and statistical significance will be designated as P < 0.05. The outcomes of
FEV1 % predicted, exacerbation frequency, and QOL scores are all continuous variables
and will be described as means with standard deviations. Unpaired Student’s t-tests will
be used to compare the change in FEV1, change in CFQ-R score, and the difference in
exacerbation frequency between the 2 groups. Paired Student’s t-tests will be used to
compare the change in FEV1 CFQ-R score within the same subjects from baseline. If data
is not normally distributed, then paired and unpaired Wilcoxon’s rank-sum tests will be
used instead. As FEV1 and CFQ-R scores will be measured quarterly, those time points
will be compared using unpaired Student’s t-tests. To look at the effect of the
intervention in specific groups, results will also be stratified by CFTR genotype,
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colonization with Pseudomonas aeruginosa, colonization with Burkholderia cepacia, and
type of CFTR modulator medication used.
Table 2. Sample Table of Baseline Characteristics of Subjects
Characteristic
Structured
Non-Structured
Sample Size (n)
Gender (% F, %M, % Other)
Age (Years)
Race (White, African American,
Hispanic, Other)
FEV1 (% Predicted)
CFQ-R Score (Points)

P value

3.12 Timeline and Resources
Before recruitment begins, the Human Investigation Committee (HIC) process is
estimated to take 2-3 months. The recruitment phase and intervention phase will be a
total of 2 years. Upon completion of the intervention period, data analysis is estimated to
take 2-3 months.
Figure 3. Proposed Study Phases
HIC Review
(2-3 Months)

Recruitment
Phase (12
Months)

Intervention
Phase (12
Months)

Data
Analysis ( 23 Months)

The personnel required to complete this study includes the CF team who the
patient normally sees every 3 months, including the physician and the respiratory
therapist to perform the spirometry, and a research assistant for recruitment assistance
and data entry. The principal investigator will also perform recruitment assistance as well
as conduct the monthly phone calls. As the study is utilizing the patients’ already
scheduled 3-month visits, additional office space for appointments will not be needed.
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Chapter 4 – Conclusion
4.1 Advantages and Disadvantages
Our proposed study has several advantages over previous studies that investigated
the relationships between lung function, exercise, and ACT in patients with CF. First, our
intervention period of 1 year is longer than most studies and will provide a longitudinal
look at FEV1 measurements to ensure sustained results. As a result, our findings will give
greater insight into the long-term benefits of ACT and exercise as opposed to their
immediate effects. Additionally, our study takes advantage of the already scheduled
appointments that patients with CF have quarterly, thus decreasing the time burden of
appointments for our participants.
Another strength of this study is that we are aiming to create an exercise and ACT
regimen that could feasibly be implemented into the lives of those with CF. In contrast to
studies that have directly supervised or closely monitored exercise sessions, our exercise
regimen will be performed individually. Also, ACT will be performed with the
participants’ modality of choice and for the amount of time instructed by their providers.
Overall, we believe this makes the intervention more generalizable to those with CF
because it does not require additional resources like trainers or new ACT modalities.
An important limitation of our study design is that a less-regulated structure
allows for variability in the intensity of the exercise performed by the participants, and
we must rely on self-reported adherence. This also means that participants will be
completing different forms of ACT for different time periods. However, the different
forms of ACT should not cause a significant difference in change in lung function, as
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previous studies have shown no significant differences between the modalities.
Furthermore, since this study takes place over 1 year and subjects have varying lung
function status, it would pose a risk to the subjects if they were instructed to perform the
same length and frequency of ACT.
Another limitation of our study design as an at-home program is that it requires a
certain level of motivation from the patients to fully participate. Yet, we believe this is an
acceptable limitation because outside of the study, those who would implement the
regimen into their lifestyle would need to have some level of motivation as well.
Regardless, the results of this study are not as generalizable to those who either do not
desire or do not have the ability to exercise regularly.
4.2 Clinical and Public Health Significance
The addition of CF treatments to other personal responsibilities for adults with CF
can be burdensome. Therefore, the treatments that patients perform should be beneficial
to their health to maximize their use of time. Both exercise and ACT are recommended
therapies, but a program that combines both may provide even greater effects on lung
function. Preservation of lung function in patients with CF is extremely important in
preventing health decline and further sequelae of the disease. The proposed study will
start to examine this relationship between the timing and integration of exercise and ACT
on lung function longitudinally.
If an integrated exercise and ACT program is found to improve lung function,
then CF providers will have a specific regimen to provide to their patients. Importantly,
the regimen still allows for personal adjustments and preferences, so it can be
individually tailored for each subject. Hopefully, the integrated program will also
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increase patient adherence to exercise and ACT both as a result of improved lung
function as well as the feasibility of implementation into daily life. In addition to
improved lung function, if the intervention decreases exacerbation frequency, this will
also drastically affect the daily lives of patients. Fewer exacerbations would better
preserve lung function and lessen the need for antibiotics and hospitalizations. These
results could ultimately lead to an improved quality of life for patients with CF.
If the proposed integrated program does not have a significant effect on lung
function in the study, then perhaps the order and timing of ACT and exercise are not as
important as long as they are completed. If this is the case, ACT and exercise should
continue to be recommended to patients, but it could be argued that the combination does
not maximize benefits. The results of the secondary outcomes must also be considered in
this situation because it could be possible that the intervention does not significantly
affect lung function, but it may decrease exacerbations or improve quality of life, both of
which are likely valued by patients with CF. Either way, the results of this study will
provide greater insight into the best methods for patients to perform exercise and ACT.
Additionally, the details of the intervention (time and frequency of exercising, monitoring
of exercise, ACT session length and frequency, etc.) could be adjusted for future studies
to determine the most effective regimen to improve lung function.
In conclusion, the integration of ACT and exercise in patients with CF has an
encouraging potential to improve lung function over time. The proposed study will allow
CF providers to make recommendations for ACT and exercise to their patients based on
long-term results of lung function and exacerbation frequency. Overall, this study has the
potential to greatly improve the quality of life for those living with CF.
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Appendices
Appendix A. Sample Consent Form
Written with the 200 FR.1 HIC Consent Template
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
200 FR. 1 (2016-2)
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE NEW HAVEN
HOSPITAL
Study Title: A Structured Airway Clearance and Exercise Program to Improve Clinical
Outcomes in Cystic Fibrosis
Principal Investigator: Rachel Rose, PA-SII
Co-Principal Investigator: Clemente Britto-Leon, MD
Invitation to Participate and Description of Project
We are inviting you to participate in a research study designed to evaluate the
effectiveness of an integrated exercise and airway clearance therapy on lung function in
adults with cystic fibrosis. You have been asked to participate because you have been
diagnosed with cystic fibrosis and you are older than 18 years. Approximately 77 people
will participate in this study.
Before you decide if you want to partake in this research study, it is important that you
are aware of the risks and benefits in order to make an informed decision. This consent
form will present you with information regarding the study, and this will be discussed
with a research team member. The details to be discussed include the purpose, procedures
to be performed, possible risks and benefits, and possible alternative treatments. Upon
reading this form, you will be asked to sign this form if you wish to participate.
Description of Procedures
If you choose to participate in this study, you will be randomly assigned to either the
intervention group or the control group. In the intervention group, you will be asked to
perform an integrated program of exercise and airway clearance therapy (ACT). This will
entail performing 30 minutes of exercise prior to an ACT session three times per week.
You may choose your type of exercise from a list of accepted forms, and you will be
asked to measure your heart rate before, once during, and after the 30 minutes of
exercise. You will receive instructions on how to measure your heart rate prior to starting
the study.
In the control group, you will be asked to perform 30 minutes of exercise from a list of
accepted forms three times weekly. The exercise sessions must be separated by any ACT
sessions by at least 2 hours. You will be asked to measure your heart rate before, once
during, and after exercise, and you will receive instruction on how to measure your heart
rate prior to starting the study.
In both groups, you will be asked to continue your CF appointments at the adult CF clinic
every three months where you will perform spirometry and fill out a questionnaire on
quality of life. You will also receive a phone call on the months that you do not have an
appointment to discuss any questions. Additionally, you will be asked to fill out a daily
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journal to record activity levels. The journal will include type of exercise performed, type
of ACT performed, length of ACT performed, any side effects noticed, and heart rate
measurements. This study will last for a time period of one year.
During the study, you may continue any other treatments you are receiving. You will not
be standardized to a specific amount or method of ACT, and you should continue this as
prescribed by your provider.
As required by U.S. Law, a description of this study can be found on
http://www.ClinicalTrials.gov. This is a database that is used for people to see what
studies are being done and what studies have been completed. The website will not
include any information that can identify you, and will, at most, show a summary of the
results. You may search this website at any time.
You will be told of any significant new findings that are developed during the course of
your participation in this study that may affect your willingness to continue to participate.
If research results are published, your name and other personal information will not be
given.
Risks and Inconveniences
Both exercise and airway clearance therapy have been studied in many clinical trials, and
they are recommended in the treatment of cystic fibrosis. The incidence of side effects in
previous similar studies is rare, but they can occur.
Exercising carries certain risks or bodily harm that includes: physical injury (strain,
fracture, etc.), acute dyspnea and cough, hypoglycemia, worsening of arthritis, cardiac
arrhythmias, pneumothorax, and loss of consciousness. Some people may also experience
soreness or stiffness after exercise. We will minimize these risks by encouraging you to
wear proper clothing and shoes for exercise. We also ask that you discontinue exercising
if you experience any side effects and either call the number listed on your daily journal
or record the event in your daily journal.
Other risks from participating in the study include the breach of confidentiality about
your health status and participation in the study. This is very unlikely to occur, as all
study investigators are trained and certified in research privacy.
In the case of injury during the study, Yale School of Medicine and Yale New Haven
Hospital will not cover the costs of a research-related injury. If you are injured, treatment
will be provided, but you or your insurance carrier will be expected to pay for the
treatment costs. There is no additional monetary compensation if you are injured.
Benefits
The results from this study may provide greater insight into the most effective integration
of both exercise and ACT as CF therapies. The potential benefits of this study include
improved lung function, decreased exacerbations, and improved health-related quality of
life.
Economic Considerations
There are no costs associated with your participation in the study.
Treatment Alternatives/Alternatives
If you decide not to participate in this study, the alternative treatment is to continue your
current regimen of exercise and ACT as recommended by your provider.
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Confidentiality and Privacy
Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as required by U.S. or
State law. Examples of information that we are legally required to disclose include abuse
of a child or elderly person, or certain reportable diseases. Data will be stored on a
HIPAA compliant and encrypted device that is password protected. When the results of
the research are published or discussed in conferences, no information will be included
that would reveal your identity unless your specific permission for this activity is
obtained.
We understand that information about your health is personal, and we are committed to
protecting the privacy of that information. If you decide to be in this study, the researcher
will get information that identifies your personal health information. This may include
information that might directly identify you, such as his or her name and address,
telephone number, and email address, or mobile phone number. This information will be
de-identified at the earliest reasonable time after we receive it, meaning we will replace
your identifying information with a code that does not directly identify you. The principal
investigator will keep a link that identifies you and your coded information, and this link
will be kept secure and available only to the principal investigator or selected members of
the research team. Any information that can identify you will remain confidential. The
research team will only give this coded information to others to carry out this research
study. The link to your personal information will be kept for 5 years, after which time the
link will be destroyed and the data will become anonymous. The data will be kept in this
anonymous form indefinitely.
The information about your health that will be collected in this study includes:
• Results of lung function testing and health-related quality of life survey answers
• Records about the monthly phone calls made as part of this research
• Records in medical chart regarding exacerbations during study period
Information about your health which might identify you may be used by or given to:
• The U.S. Department of Health and Human Services (DHHS) agencies
• Representatives from Yale University, the Yale Human Research Protection
Program and the Yale Human Investigation Committee (the committee that
reviews, approves, and monitors research on human subjects), who are
responsible for ensuring research compliance. These individuals are required to
keep all information confidential.
By signing this form, you authorize the use and/or disclosure of the information described
above for this research study. The purpose for the uses and disclosures you are
authorizing is to ensure that the information relating to this research is available to all
parties who may need it for research purposes.
All health care providers subject to HIPAA (Health Insurance Portability and
Accountability Act) are required to protect the privacy of your information. The research
staff at the Yale School of Medicine are required to comply with HIPAA and to ensure
the confidentiality of your child’s information.
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If you choose to participate in this study, the investigators will check your electronic
medical record at Yale (EPIC) to make sure you qualify. Any access to your electronic
medical record will be done consistent with HIPAA regulations.
Some of the individuals or agencies listed above may not be subject to HIPAA and
therefore may not be required to provide the same type of confidentiality protection. They
could use or disclose your information in ways not mentioned in this form. However, to
better protect your health information, agreements are in place with these individuals
and/or companies that require that they keep your information confidential.
You have the right to review and copy your health information in your medical record in
accordance with institutional medical records policies. This authorization to use and
disclose your health information collected during your participation in this study will
never expire.
Voluntary Participation
You are free to choose not to participate in this study. Your health care outside the study,
the payment for your health care, and your health care benefits will not be affected if you
do not agree to participate. However, you will not be able to enroll in this research study
and will not receive study procedures as a study participant if you do not allow use of
your information as part of this study.
Withdrawing From the Study
If you do become a subject, you are free to stop and withdraw from this study at any time
during its course. To withdraw from the study, you can call a member of the research
team at any time and tell them that you no longer want to take part.
The researchers may withdraw you from participating in the research if necessary. This
includes, but is not limited to, non-compliance (i.e. not attending appointments) or in the
cases of serious side effects.
If you choose not to participate or if you withdraw it will not harm your relationship with
your own doctors or with the Yale School of Medicine and Yale New-Haven Hospital.
When you withdraw your permission, no new health information identifying you will be
gathered after that date. Information that has already been gathered may still be used and
given to others until the end of the research study, as necessary to insure the integrity of
the study and/or study oversight.
You do not give up any of your legal rights by signing this form.
Questions
As this form contains detailed information and technical terms, please feel free to ask any
questions regarding the study. You may take as much time as you need to consider
joining this study before you make a final decision.
Authorization
I have read (or someone has read to me) this form and have decided to participate in the
project described above. Its general purposes, the particulars of my involvement and
possible hazards and inconveniences have been explained to my satisfaction. My
signature also indicates that I have received a copy of this consent form.
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Name of Subject:_____________________________
Signature:___________________________________
Relationship:________________________________
Date:______________________________________
___________________________________________ ___________________
Signature of Principal Investigator
Date
or
___________________________________________ ___________________
Signature of Person Obtaining Consent
Date
If you have further questions about this project, or if you have a research-related problem,
you may contact the Principal Investigator, Rachel Rose PA-SII (***) ***- **** or the
Co-Principal Investigator, Clemente Britto-Leon, MD (***) *** -****.
If, after you have signed this form you have any questions about your privacy rights,
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with
someone other than the researchers to discuss problems, concerns, and questions you may
have concerning this research, or to discuss your rights as a research subject, you may
contact the Yale Human Investigation Committee at (203) 785-4688.
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Appendix B. Sample Recruitment Flyer

Volunteers Needed for a Cystic
Fibrosis Research Study
We are looking for participants in a study to determine if
combining exercise with airway clearance therapy improves lung
function, decreases exacerbations, and improves quality of life in
people with cystic fibrosis.
You May Be Eligible If:
• You have been diagnosed with cystic fibrosis
• You are at least 18 years of age
• You are able to participate in exercise
• You are currently performing some form of airway clearance therapy
What Will You Have to Do?
• Complete 30 minutes of exercise three times per week
• Fill out a daily journal
o Record the amount of time and type of exercise and airway
clearance therapy performed
o Record your heart rate before, during, and after exercise
• Continue attending quarterly CF appointments for spirometry and to
fill out a quality of life questionnaire

If you are interested in participating, or if you have any
questions, please contact:
Rachel Rose, Principal Investigator: (***)***-**** or at
********@yale.edu

You may also discuss this with your CF provider at your
next visit!
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Appendix C. Sample CFQ-R Survey
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Appendix D. List of Exercise Options
You may choose any form of exercise listed below to complete your 30 minutes of
exercise 3 times per week:
•

Running

•

Fast Walking

•

Biking

•

Hiking

•

Aerobics Class

•

Jumping (Jump Rope, Trampoline, etc.)

•

Kickboxing

•

Boxing

•

Swimming

•

Circuit Training

•

Dancing

•

Rowing

•

High-intensity Interval Training

•

Elliptical

•

Stair Machine

•

Cross-country Skiing

•

Basketball

•

Soccer

If you have any other preferred exercises, please contact our research team at
(***)***-**** to see if it qualifies for this study.
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Appendix E: Sample Exercise and ACT Daily Log
Directions: Please fill out one row of the table below every day. Under “Exercise
Minutes” and “ACT Minutes,” record the number of minutes spent on each therapy, and
under “Exercise Activity” and “ACT Method,” write what type of exercise you
completed and which type of ACT you used. On days you do not exercise or do ACT,
record 0 minutes and leave the activity or method box blank. The “Side Effects” column
is for you to record any side effects you notice while completing the exercise and ACT. If
you do not experience any side effects, leave the box blank.
On the three days per week that you exercise, record your heart rate before exercise (#1),
once in the middle of exercise (around 15 minutes, #2), and after completing exercise
(#3). Please calculate your heart rate as demonstrated by our research team at your first
appointment. Also, use the target heart rate you have been provided with as a goal—If
your heart rate is lower than the target in the middle of exercise, then increase the
intensity of exercise as tolerated.
Please bring this log with you to all of your appointments at your CF clinic over the next
year. If you have any questions, contact our research team at (***) *** - ****.
Date

Exercise
Activity

Exercise
Minutes

ACT
Method

ACT
Minutes
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Heart Heart Heart
Rate Rate Rate
#1
#2
#3

Side Effects

Appendix F. Calculations for Target Heart Rate
1. Maximum heart rate will be calculated according to CDC guidelines1:
220 – Age (In Years)
2. Target heart rate will be in the range of 70-85% of maximum heart rate:
.70 (Maximum HR) to 0.85 (Maximum HR)

Example: For a person 25 years of age…
Maximum Heart Rate: 220 - 25 = 195
0.70 (195) = 136.5
0.85 (195) = 165.75
Target Heart Rate Range: 137 – 166 beats per minute
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Appendix G. Sample Size Calculation
Sample size calculation based on:
Alpha (α, level of significance) = 0.050
B (β, type II error) = 0.10, Power of 90%
μ1 = 5.76% ± 3.70
μ2 = -4.42% ± 14.70
n = 25 per group
Adding an additional 10 subjects to each arm plus a 10% dropout rate results in a total
sample size of n = 77

Calculated using Power and Precision. Version 4.0. Biostat, Inc. Englewood, New Jersey.
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